Association Between PDL1 Genetic Variation and Efficacy of Apatinib Monotherapy in Patients with Previously Treated Advanced NSCLC: A Real-World Retrospective Study

References

• Xu K, Zhang C, Du T, et al. Progress of exosomes in the diagnosis and treatment of lung cancer. Biomed Pharmacother. 2021;134:111111. doi:10.1016/j.biopha.2020.111111.
   PubMed Web of Science ®Google Scholar
• Zhang J, Mao W, Chen Z, Gu H, Lian C. Clinical Significance of Has_circ_0060937 in Bone Metastasis of NSCLC. Int J Gen Med. 2020;13:1115–1121. doi:10.2147/ijgm.s279023.
   PubMed Web of Science ®Google Scholar
• Phan TT, Ho TT, Nguyen HT, et al. The prognostic impact of neutrophil to lymphocyte ratio in advanced non-small cell lung cancer patients treated with EGFR TKI. Int J Gen Med. 2018;11:423–430. doi:10.2147/ijgm.s174605.
   PubMed Web of Science ®Google Scholar
• Arbour KC, Riely GJ. Systemic Therapy for Locally Advanced and Metastatic Non-Small Cell Lung Cancer: a Review. JAMA. 2019;322(8):764–774. doi:10.1001/jama.2019.11058.
   PubMed Web of Science ®Google Scholar
• Ghadyalpatil NS, Pandey A, Krishnamani I, et al. First-line management of metastatic non-small cell lung cancer: an Indian perspective. South Asian J Cancer. 2019;8(2):73–79. doi:10.4103/sajc.sajc_294_18.
   PubMed Web of Science ®Google Scholar
• Garassino MC, Kawaguchi T, Gregorc V, et al. Chemotherapy versus erlotinib as second-line treatment in patients with advanced non-small cell lung cancer and wild-type epidermal growth factor receptor: an individual patient data (IPD) analysis. ESMO Open. 2018;3(6):e000327. doi:10.1136/esmoopen-2018-000327.
   PubMed Web of Science ®Google Scholar
• Huang L, Li L, Zhou Y, et al. Clinical Characteristics Correlate With Outcomes of Immunotherapy in Advanced Non-Small Cell Lung Cancer. J Cancer. 2020;11(24):7137–7145. doi:10.7150/jca.49213.
   PubMed Web of Science ®Google Scholar
• Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285(21):1182–1186. doi:10.1056/nejm197111182852108.
   PubMed Web of Science ®Google Scholar
• Manzo A, Montanino A, Carillio G, et al. Angiogenesis Inhibitors in NSCLC. Int J Mol Sci. 2017;18(10):10. doi:10.3390/ijms18102021.
   Web of Science ®Google Scholar
• Han B, Li K, Wang Q, et al. Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: the ALTER 0303 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2018;4(11):1569–1575. doi:10.1001/jamaoncol.2018.3039.
   PubMed Web of Science ®Google Scholar
• Li J, Qin S, Xu J, et al. Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction. J Clin Oncol. 2016;34(13):1448–1454. doi:10.1200/jco.2015.63.5995.
   PubMed Web of Science ®Google Scholar
• Zhao D, Hou H, Zhang X. Progress in the treatment of solid tumors with apatinib: a systematic review. Onco Targets Ther. 2018;11:4137–4147. doi:10.2147/ott.s172305.
   PubMed Web of Science ®Google Scholar
• Villaruz LC, Socinski MA. The role of anti-angiogenesis in non-small-cell lung cancer: an update. Curr Oncol Rep. 2015;17(6):26. doi:10.1007/s11912-015-0448-y.
   PubMed Web of Science ®Google Scholar
• Hudson K, Cross N, Jordan-Mahy N, Leyland R. The Extrinsic and Intrinsic Roles of PD-L1 and Its Receptor PD-1: implications for Immunotherapy Treatment. Front Immunol. 2020;11:568931. doi:10.3389/fimmu.2020.568931.
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. N Engl J Med. 2018;379(21):2040–2051. doi:10.1056/NEJMoa1810865.
   PubMed Web of Science ®Google Scholar
• Yi M, Jiao D, Qin S, et al. Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment. Mol Cancer. 2019;18(1):60. doi:10.1186/s12943-019-0974-6.
   PubMed Web of Science ®Google Scholar
• Wu Y, Zhao T, Jia Z, et al. Polymorphism of the programmed death-ligand 1 gene is associated with its protein expression and prognosis in gastric cancer. J Gastroenterol Hepatol. 2019;34(7):1201–1207. doi:10.1111/jgh.14520.
   PubMed Web of Science ®Google Scholar
• Su J, Dai B, Yuan W, et al. The influence of PD-L1 genetic variation on the prognosis of R0 resection colorectal cancer patients received capecitabine-based adjuvant chemotherapy: a long-term follow-up, real-world retrospective study. Cancer Chemother Pharmacol. 2020;85(5):969–978. doi:10.1007/s00280-020-04069-1.
   PubMed Web of Science ®Google Scholar
• Flaifel A, Xie W, Braun DA, et al. PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: analysis of the Randomized Clinical Trials METEOR and CABOSUN. Clin Cancer Res. 2019;25(20):6080–6088. doi:10.1158/1078-0432.ccr-19-1135.
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247. doi:10.1016/j.ejca.2008.10.026.
   PubMed Web of Science ®Google Scholar
• Miller TP, Fisher BT, Getz KD, et al. Unintended consequences of evolution of the Common Terminology Criteria for Adverse Events. Pediatr Blood Cancer. 2019;66(7):e27747. doi:10.1002/pbc.27747.
   PubMed Web of Science ®Google Scholar
• Song ZZ, Zhao LF, Zuo J, et al. Clinical Outcomes and Safety of Apatinib Mesylate in the Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer in Patients Who Progressed After Standard Therapy and Analysis of the KDR Gene Polymorphism. Onco Targets Ther. 2020;13:603–613. doi:10.2147/ott.s222985.
   PubMed Web of Science ®Google Scholar
• Ma JT, Sun J, Sun L, et al. Efficacy and safety of apatinib in patients with advanced nonsmall cell lung cancer that failed prior chemotherapy or EGFR-TKIs: a pooled analysis. Medicine. 2018;97(35):e12083. doi:10.1097/md.0000000000012083.
   PubMed Web of Science ®Google Scholar
• Fang SC, Huang W, Zhang YM, Zhang HT, Xie WP. Hypertension as a predictive biomarker in patients with advanced non-small-cell lung cancer treated with apatinib. Onco Targets Ther. 2019;12:985–992. doi:10.2147/ott.s189984.
   PubMed Web of Science ®Google Scholar
• Zhang D, Zhang C, Huang J, Guan Y, Guo Q. Clinical investigation of the efficacy and toxicity of apatinib (YN968D1) in stage III/IV non-small cell lung cancer after second-line chemotherapy treatment: a retrospective study. Thorac Cancer. 2018;9(12):1754–1762. doi:10.1111/1759-7714.12898.
   PubMed Web of Science ®Google Scholar
• Agemi Y, Shimokawa T, Sasaki J, et al. Prospective evaluation of the G8 screening tool for prognostication of survival in elderly patients with lung cancer: a single-institution study. PLoS One. 2019;14(1):e0210499. doi:10.1371/journal.pone.0210499.
   PubMed Web of Science ®Google Scholar
• Nadal E, Massuti B, Domine M, et al. Immunotherapy with checkpoint inhibitors in non-small cell lung cancer: insights from long-term survivors. Cancer Immunol Immunother. 2019;68(3):341–352. doi:10.1007/s00262-019-02310-2.
   PubMed Web of Science ®Google Scholar
• Xie Q, Chen Z, Xia L, et al. Correlations of PD-L1 gene polymorphisms with susceptibility and prognosis in hepatocellular carcinoma in a Chinese Han population. Gene. 2018;674:188–194. doi:10.1016/j.gene.2018.06.069.
   PubMed Web of Science ®Google Scholar
• Catalano C, da Silva Filho MI, Frank C, et al. Investigation of single and synergic effects of NLRC5 and PD-L1 variants on the risk of colorectal cancer. PLoS One. 2018;13(2):e0192385. doi:10.1371/journal.pone.0192385.
   PubMed Web of Science ®Google Scholar
• Hashemi M, Karami S, Sarabandi S, et al. Association between PD-1 and PD-L1 Polymorphisms and the Risk of Cancer: a Meta-Analysis of Case-Control Studies. Cancers. 2019;11(8):1150. doi:10.3390/cancers11081150.
   PubMed Web of Science ®Google Scholar
• Isobe K, Kakimoto A, Mikami T, et al. PD-L1 mRNA expression in EGFR-mutant lung adenocarcinoma. Oncol Rep. 2018;40(1):331–338. doi:10.3892/or.2018.6442.
   PubMed Web of Science ®Google Scholar
• Du W, Zhu J, Chen Y, et al. Variant SNPs at the microRNA complementary site in the B7H1 3ʹuntranslated region increase the risk of nonsmall cell lung cancer. Mol Med Rep. 2017;16(3):2682–2690. doi:10.3892/mmr.2017.6902.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Zhao Y, Lu F, et al. Multi-targeted tyrosine kinase inhibitors as third-line regimen in advanced non-small cell lung cancer: a network meta-analysis. Ann Transl Med. 2019;7(18):452. doi:10.21037/atm.2019.08.51.
   PubMed Web of Science ®Google Scholar
• Miyawaki E, Murakami H, Mori K, et al. PD-L1 expression and response to pembrolizumab in patients with EGFR-mutant non-small cell lung cancer. Jpn J Clin Oncol. 2020;50(5):617–622. doi:10.1093/jjco/hyaa033.
   PubMed Web of Science ®Google Scholar
• Xu Y, Wan B, Chen X, et al. The association of PD-L1 expression with the efficacy of anti-PD-1/PD-L1 immunotherapy and survival of non-small cell lung cancer patients: a meta-analysis of randomized controlled trials. Transl Lung Cancer Res. 2019;8(4):413–428. doi:10.21037/tlcr.2019.08.09.
   PubMed Web of Science ®Google Scholar
• Kim T, Cha YJ, Chang YS. Correlation of PD-L1 Expression Tested by 22C3 and SP263 in Non-Small Cell Lung Cancer and Its Prognostic Effect on EGFR Mutation-Positive Lung Adenocarcinoma. Tuberc Respir Dis. 2020;83(1):51–60. doi:10.4046/trd.2019.0026.
   PubMed Web of Science ®Google Scholar
• Gennen K, Kasmann L, Taugner J, et al. Prognostic value of PD-L1 expression on tumor cells combined with CD8+ TIL density in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy. Radiat Oncol. 2020;15(1):5. doi:10.1186/s13014-019-1453-3.
   PubMed Web of Science ®Google Scholar
• Berntsson J, Eberhard J, Nodin B, et al. Expression of programmed cell death protein 1 (PD-1) and its ligand PD-L1 in colorectal cancer: relationship with sidedness and prognosis. Oncoimmunology. 2018;7(8):e1465165. doi:10.1080/2162402x.2018.1465165.
   PubMed Web of Science ®Google Scholar